[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576117":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":11,"responsibleParty":30,"collaborators":11,"id":32,"slug":11,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":11,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":11,"studyType":44,"phases":45,"briefSummary":48,"conditions":49,"keywords":11,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":11},{"fullName":5,"class":6},"Immorna Biotherapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase Ia will be planned in 2 dose groups, Phase Ib will select the optimal dose based Phase Ia","EXPERIMENTAL",null,[13],"Drug: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion","JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .\n\nAnti-PD-1 antibody:Dosage and administration according to the instructions.",[9],[21],{"name":22,"affiliation":23,"role":24},"RuiHua Xu","Sun Yat-Sen University Cancer Center","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","86-20-87343468","xurh@sysucc.org.cn",{"type":31,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100576117",false,"NCT06781125","One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","A Phase I\u002FII Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients, aged 18 to 75 years;\n2. patients with malignant solid tumors confirmed by pathology and\u002For cytology who have progressed or are intolerant to standard treatment (except best supportive care); Including patients who have received prior anti-PD-1 antibody therapy; patients who have been approved as eligible for Toripalimab:\n3. General condition score ECOG 0 \\~ 1;\n4. Expected survival of more than 3 months;\n\nExclusion Criteria:\n\n1. Known or suspected allergy to the ingredients of the study drug or its analogues; allergic history to another monoclonal antibody;\n2. patients who have previously received IL-12 therapy (alone or as part of a treatment regimen), except those who have participated in tolerance to a single intratumoral injection;\n3. patients who have previously received treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or have received treatment directed at another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137), and discontinued treatment due to Grade 3 or higher immune-related adverse events (irAEs);","ALL","18 Years","75 Years",{"count":42,"type":43},72,"ESTIMATED","INTERVENTIONAL",[46,47],"PHASE1","PHASE2","This is an open-label, dose-escalation and dose-expansion Phase I \u002FII clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.",[50],"Malignant Solid Tumors","NOT_YET_RECRUITING","2026-03-20",{"date":54,"type":55},"2026-03-24","ACTUAL",{"date":57,"type":43},"2026-03-18",{"date":59,"type":43},"2028-06-30",{"name":5,"class":6}]